CureVac Company Description

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.

CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.

Country	Netherlands
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	1,172
CEO	Alexander Zehnder

Contact Details

Address: Friedrich-Miescher-Strasse 15 Tübingen, 72076 Germany
Phone	49 7071 9883 0
Website	curevac.com

Stock Details

Ticker Symbol	5CV
Exchange	Deutsche Börse Xetra
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	NL0015436031
SIC Code	2836

Key Executives

Name	Position
Dr. Alexander Zehnder M.B.A., M.D.	Chief Executive Officer, MD and Member of Management Board
Dr. Malte Greune Ph.D.	Chief Operating Officer, Member of Management Board and MD
Dr. Myriam Mendila M.D.	Chief Scientific Officer, Head of Research & Development, MD and Member of the Management Board
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior Vice President and Area Head of Oncology
Axel-Sven Malkomes	Chief Financial Officer and Member of Executive Board
Thaminda Ramanayake	Chief Business Officer and Member of Executive Board
Dr. Sarah Fakih	Vice President Corporate Communications and Investor Relations
Marco Rau L.L.M., Ph.D.	General Counsel
Thorsten Schuller	Head of Corporate Communications
Slavica Stevanovic-Heck	Head of Human Resources